Intraocular pressure changes in non-glaucomatous patients receiving intravitreal anti-vascular endothelial growth factor agents

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Kiddee, Weerawat ^a   Montriwet, Mayuree ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; FOLLOW UP; GOLDMANN APPLANATION TONOMETER; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PROSPECTIVE STUDIES; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84945271403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137833     Document Type: Article

References (22)

1. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. CurrOpin Ophthalmol. 2010; 21: 218-226. doi: 10.1097/ICU.0b013e3283386783 PMID: 20393293
2. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908. doi: 10.1056/NEJMoa1102673 PMID: 21526923
3. Van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011; 31: 1449-1469. doi: 10.1097/IAE.0b013e3182278ab4 PMID: 21817960
4. Axer-Siegel R, Bor E, Bourla DH, Weinberger D, Mimouni K. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. Retina 2012; 32: 1811-1820. PMID: 22825407
5. Tolentino M. Systemic and ocular safety of intravitreal antiVEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56: 95-113. doi: 10.1016/j.survophthal.2010.08.006 PMID: 21335144
6. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007; 27: 1044-1047. PMID: 18040242
7. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18: 658-661. doi: 10.1097/IJG.0b013e31819c4893 PMID: 20010243
8. Kim JE, Mantravadi AV, Hur E, Covert AJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008; 146: 930-934. doi: 10.1016/j.ajo.2008.07.007 PMID: 18775528
9. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-811. PMID: 18026202
10. Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. Alack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012; 32: 1295-1301. PMID: 22466465
11. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246: 955-958. doi: 10.1007/s00417-008-0819-2 PMID: 18425523
12. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009; 40: 293-295. PMID: 19485295
13. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010; 26: 105-110. doi: 10.1089/jop.2009.0076 PMID: 20187807
14. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 2010; 4: 28-29. doi: 10.2174/1874364101004010028 PMID: 20871754
15. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011; 95: 1111-1114. doi: 10.1136/bjo.2010.180729 PMID: 20702430
16. Choi DY, Ortube MC, McCannel CA, Sarraf D, Hubschman JP, McCannel TA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and Pegaptanib. Retina 2011; 31: 1028-1035. doi: 10.1097/IAE.0b013e318217ffde PMID: 21836409
17. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012; 119: 321-326. doi: 10.1016/j.ophtha.2011.08.011 PMID: 22054994
18. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012; 21: 241-247. doi: 10.1097/IJG.0b013e31820d7d19 PMID: 21423038
19. Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1435-1440. doi: 10.1007/s00417-012-1981-0 PMID: 22434210
20. Aref AA Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. CurrOpin Ophthalmol 2012; 23: 105-110. doi: 10.1097/ICU.0b013e32834ff41d PMID: 22249237
21. Hoang QV, Tsuang AJ, Gelman R, Mendonca LS, Della Torre KE, Jung JJ, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013; 33: 179-187. doi: 10.1097/IAE.0b013e318261a6f7 PMID: 22990314
22. Kernt M, Welge-Lüssen U, Yu A, Neubauer AS, Kampik A. Bevacizumab is not toxic to human anterior-and posterior-segment cultured cells. Ophthalmologe 2007; 104: 965-971. PMID: 17653724